Biopharmaceutical company Oakrum Pharma LLC revealed on Monday the launch of an agreement to develop and manufacture two prescription generic pharmaceutical products to be commercialised in the US under the Oakrum label.
The company said it has signed the product development and commercialisation partnership with Biophore India Pharmaceuticals Pvt Ltd, a pharmaceutical company.
Both the prescription generic pharmaceutical products are expected to be sold through the specialty distribution market channel.
For the 12-month period ending 31 December 2018, the total market for the products in the US exceeded USD150m in aggregate sales, according to Bloomberg data.
Alvotech signs biosimilar supply and commercialisation deals with Sandoz
InSysBio agrees new collaborative project with BeOne Medicines
MS Pharma enters strategic partnership with Hetero Group
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
Zentiva receives ESG Transparency Award 2025
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis